Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nexstim Plc, a medical technology company, (NXTMH) Fair Value & Analysis

Healthcare · FI · Market cap €63.4M

Price€9.90
Fair Value€1.74
Upside-82.4%
Quality95/100
Evidence: Medium Range €1.31 – €2.18

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Nexstim Plc, a medical technology company, (NXTMH) currently trades at €9.90, while our model-based Fair Value estimate is €1.74 — implying the stock looks roughly 82.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Nexstim Plc, a medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company offers non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS), including Navigated Brain Stimulation (NBS) system 6 for presurgical mapping of the speech and motor cortices of the brain, for the treatment of major depression and chronic unilateral neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb. The company markets and sells its diagnostics systems to universities and teaching hospitals. It has an exclusive collaboration with Sinaptica Therapeutics, Inc. for the development, manufacture, and delivery of precision neuromodulation system for the treatment of Alzheimer's disease and mild cognitive impairment; and a development and distribution collaboration with Brainlab AG for motor and speech mapping systems. The …

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -9% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Nexstim Plc, a medical technology company, (NXTMH) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €1.74 versus a price of €9.90 — about −82% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NXTMH?
Our 21-model fair value for Nexstim Plc, a medical technology company, is €1.74 (as of Jun 24, 2026), built from audited fundamentals. The current price is €9.90.
What is the quality score of NXTMH?
Nexstim Plc, a medical technology company, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.